PT  - JOURNAL ARTICLE
AU  - Moreno-García, Estela
AU  - Rico, Verónica
AU  - Albiach, Laia
AU  - Agüero, Daiana
AU  - Ambrosioni, Juan
AU  - Bodro, Marta
AU  - Cardozo, Celia
AU  - Chumbita, Mariana
AU  - De la Mora, Lorena
AU  - García-Pouton, Nicole
AU  - Garcia-Vidal, Carolina
AU  - González-Cordón, Ana
AU  - Hernández-Meneses, Marta
AU  - Inciarte, Alexy
AU  - Laguno, Montse
AU  - Leal, Lorna
AU  - Linares, Laura
AU  - Macaya, Irene
AU  - Meira, Fernanda
AU  - Mensa, Josep
AU  - Moreno, Antonio
AU  - Morata, Laura
AU  - Puerta-Alcalde, Pedro
AU  - Rojas, Jhon
AU  - Solá, Montse
AU  - Torres, Berta
AU  - Torres, Manuel
AU  - Tomé, Adrià
AU  - Castro, Pedro
AU  - Fernández, Sara
AU  - Nicolás, Josep Maria
AU  - Almuedo-Riera, Alex
AU  - Muñoz, Jose
AU  - Fernandez-Pittol, Mariana Jose
AU  - Marcos, Maria Angeles
AU  - Soy, Dolors
AU  - Martínez, José Antonio
AU  - García, Felipe
AU  - Soriano, Alex
TI  - Tocilizumab is associated with reduced risk of ICU admission and mortality in patients with SARS-CoV-2 infection
AID  - 10.1101/2020.06.05.20113738
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.05.20113738
4099  - http://medrxiv.org/content/early/2020/06/05/2020.06.05.20113738.short
4100  - http://medrxiv.org/content/early/2020/06/05/2020.06.05.20113738.full
AB  - Background In some patients the immune response triggered by SARS-CoV-2 is unbalanced, presenting an acute respiratory distress syndrome which in many cases requires intensive care unit (ICU) admission. The limitation of ICU beds has been one of the major burdens in the management worldwide; therefore, clinical strategies to avoid ICU admission are needed.Objective We aimed to describe the influence of tocilizumab on the need of transfer to ICU or death in non-critically ill patients.Methods A retrospective study of 171 patients with SARS-CoV-2 infection that did not qualify as requiring transfer to ICU during the first 24h after admission to a conventional ward, were included. The criteria to receive tocilizumab was radiological impairment, oxygen demand or an increasing of inflammatory parameters, however, the ultimate decision was left to the attending physician judgement. The primary outcome was the need of ICU admission or death whichever came first.Results 77 patients received tocilizumab and 94 did not. The tocilizumab group had less ICU admissions (10.3% vs. 27.6%, P= 0.005) and need of invasive ventilation (0 vs 13.8%, P=0.001). In multivariable analysis, tocilizumab remained as a protective variable (OR: 0.03, CI 95%: 0.007-0·1, P=0.0001) of ICU admission or death.Conclusion Tocilizumab in the early stages of the inflammatory flare, could reduce ICU admissions and mechanical ventilation use. The mortality rate of 10.3% among patients receiving tocilizumab appears to be lower than other reports.Clinical implication Our results suggest that tocilizumab administered to non-critically ill patients could reduce ICU admissions and mortality.Capsule summary Tocilizumab administered to non-critically ill patients with SARS-CoV-2 infection in the early stages of the inflammatory flare, could reduce an important number of ICU admissions and mechanical ventilation use.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding to declareAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Ethics Committee of the Hospital Clinic of Barcelona approved the study and due to the nature of retrospective chart review, waived the need for inform consent from individual patients (Comite Etic Investigacio Clinica; HCB/2020/0273).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data of this study will be available upon request to the corresponding author.